Li Ka Hou Christien, Jesuthasan Aaron, Kui Christopher, Davies Ruth, Tse Gary, Lip Gregory Y H
Medicine, Newcastle University , Newcastle, UK.
Arrowe Park Acute Stroke Unit, Wirral University Teaching Hospital NHS Foundation Trust , Wirral, UK.
Expert Rev Neurother. 2021 Jan;21(1):65-79. doi: 10.1080/14737175.2021.1836963. Epub 2020 Nov 2.
Amongst the 25.7 million survivors and 6.5 million deaths from stroke between 1990 and 2013, ischemic strokes accounted for approximately 70% and 50% of the cases, respectively. With patients still suffering from complications and stroke recurrence, more questions have been raised as to how we can better improve patient management.
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and Newcastle-Ottawa Scale (NOS) were adopted to ensure a comprehensive inclusion of quality literature from various sources. PubMed and Embase were searched for evidence on thrombolysis, mechanical thrombectomy, artificial intelligence (AI), antiplatelet therapy, anticoagulation and hypertension management.
The directions of future research in these areas are dependent on the current level of validation. Endovascular therapy and applications of AI are relatively new compared to the other areas discussed in this review. As such, future studies need to focus on validating their efficacy. As for thrombolysis, antiplatelet and anticoagulation therapy, their efficacy has been well-established and future research efforts should be directed toward adjusting its use according to patient-specific factors, starting with factors with the most clinical relevance and prevalence.
在1990年至2013年间中风的2570万幸存者和650万死亡病例中，缺血性中风分别约占病例的70%和50%。由于患者仍遭受并发症和中风复发的困扰，人们对如何更好地改善患者管理提出了更多问题。
采用系统评价和Meta分析的首选报告项目（PRISMA）声明和纽卡斯尔-渥太华量表（NOS），以确保全面纳入来自各种来源的高质量文献。在PubMed和Embase上搜索有关溶栓、机械取栓、人工智能（AI）、抗血小板治疗、抗凝和高血压管理的证据。
这些领域未来的研究方向取决于当前的验证水平。与本综述中讨论的其他领域相比，血管内治疗和AI的应用相对较新。因此，未来的研究需要专注于验证它们的疗效。至于溶栓、抗血小板和抗凝治疗，它们的疗效已经得到充分证实，未来的研究应致力于根据患者的具体因素调整其使用，首先从具有最大临床相关性和普遍性的因素开始。
